Drawing for GILGAMESH PHARMACEUTICALS

USPTO serial 97526318

GILGAMESH PHARMACEUTICALS

Reviewed by CopyMark Law Group

Status 734Notice of Allowance
Filing date
Status date
Registration date
—
Examiner
THOMA, GABRIELLE M
Law office
INTENT TO USE SECTION

What this means

The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.

Status 734: Status 734 means the fifth and typically final extension to file a Statement of Use was granted. You must file an acceptable Statement of Use before this last extension expires or the application will abandon.

Need help with GILGAMESH PHARMACEUTICALS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $324*

Plus Government fees of $125

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Keith A. Weltsch

Keith A. Weltsch SCULLY, SCOTT, MURPHY & PRESSER, P.C.400 GARDEN CITY PLAZA, SUITE 300GARDEN CITY, NY 11530United States

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceuticals, namely, pharmaceutical and drug preparations and substances for use in treating cancer and for use in the field of neuroscience for use in the treatment and therapy of psychiatric disorders, depression disorders, substance use, substance abuse, anxiety disorders, cognitive disorders, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), bipolar disorders, eating disorders, pain, dementia, sleep disorders, attention deficit disorder, autism, and longevity; Diagnostic biomarker reagents for pharmaceutical and medical purposes; predictive biomarker reagents for medical use, namely, for pharmaceuticals and drugs for use in treating cancer and in the field of neuroscience for use in the treatment and therapy of psychiatric disorders, depression disorders, substance use, substance abuse, anxiety disorders, cognitive disorders, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), bipolar disorders, eating disorders, pain, dementia, sleep disorders, attention deficit disorder, autism, and longevityACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 21, 2026EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 21, 2026EX5GSOU EXTENSION 5 GRANTED—
Oct 20, 2026AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Jul 2, 2026TPEXSOU EXTENSION RECEIVED WITH TEAS PETITION—
Jul 2, 2026NREVNOTICE OF REVIVAL - E-MAILED—
Jul 2, 2026PETGPETITION TO REVIVE-GRANTED—
Jul 2, 2026PROATEAS PETITION TO REVIVE RECEIVED—
Jun 22, 2026MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jun 22, 2026ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
May 21, 2026EXT5SOU EXTENSION 5 FILED—
Nov 22, 2025EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Nov 21, 2025EX4GSOU EXTENSION 4 GRANTED—
Nov 21, 2025EXT4SOU EXTENSION 4 FILED—
Nov 21, 2025EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
May 17, 2025EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
May 16, 2025EX3GSOU EXTENSION 3 GRANTED—
May 16, 2025EXT3SOU EXTENSION 3 FILED—
May 16, 2025EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Mar 3, 2025EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Nov 22, 2024EX2GSOU EXTENSION 2 GRANTED—
Nov 21, 2024EXT2SOU EXTENSION 2 FILED—
Nov 21, 2024EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
May 18, 2024EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
May 17, 2024EX1GSOU EXTENSION 1 GRANTED—
May 17, 2024EXT1SOU EXTENSION 1 FILED—
May 17, 2024EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Nov 21, 2023NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Sep 26, 2023NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Sep 26, 2023PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 6, 2023NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Aug 21, 2023CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 18, 2023XAECEXAMINER'S AMENDMENT ENTERED—
Aug 18, 2023GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Aug 18, 2023GNEAEXAMINERS AMENDMENT E-MAILED—
Aug 18, 2023CNEAEXAMINERS AMENDMENT -WRITTEN—
May 25, 2023GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 25, 2023GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 25, 2023CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 16, 2023DOCKASSIGNED TO EXAMINER—
Aug 2, 2022NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 2, 2022NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance